NCT00846027 A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer Status COMPLETED Phase PHASE2
NCT00845104 Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment Status WITHDRAWN Phase PHASE2
NCT00843440 Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study Status COMPLETED Phase PHASE2
NCT00828672 Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer Status COMPLETED Phase PHASE2
NCT00828009 BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Status COMPLETED Phase PHASE2
NCT00826540 Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Status COMPLETED Phase PHASE2
NCT00820547 Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients Status COMPLETED Phase PHASE2
NCT00819780 PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors Status COMPLETED Phase PHASE2
NCT00816595 Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Status COMPLETED Phase PHASE2
NCT00815594 Bleb Vascularity Change After Subconjunctival Injection Bevacizumab Status UNKNOWN Phase PHASE4
NCT00809133 Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours Status COMPLETED Phase PHASE1
NCT00807573 Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment Status COMPLETED Phase PHASE2
NCT00805961 RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM Status COMPLETED Phase PHASE2
NCT00805649 Combined Therapy in Age-Related Macular Degeneration (ARMD) Status COMPLETED Phase PHASE4
NCT00804921 Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab Status COMPLETED Phase PHASE2
NCT00804830 Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer Status TERMINATED Phase PHASE2
NCT00804206 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Status TERMINATED Phase PHASE4
NCT00803062 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Status COMPLETED Phase PHASE3
NCT00802906 Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) Status COMPLETED Phase NA